A detailed history of Northwestern Mutual Wealth Management CO transactions in Bio N Tech Se stock. As of the latest transaction made, Northwestern Mutual Wealth Management CO holds 205 shares of BNTX stock, worth $23,191. This represents 0.0% of its overall portfolio holdings.

Number of Shares
205
Previous 101 102.97%
Holding current value
$23,191
Previous $8,000 200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$78.36 - $124.66 $8,149 - $12,964
104 Added 102.97%
205 $24,000
Q2 2024

Aug 15, 2024

SELL
$80.36 - $102.87 $723 - $925
-9 Reduced 8.18%
101 $8,000
Q1 2024

May 15, 2024

SELL
$88.96 - $112.35 $123,387 - $155,829
-1,387 Reduced 92.65%
110 $10,000
Q4 2023

Feb 13, 2024

BUY
$90.91 - $112.75 $1,545 - $1,916
17 Added 1.15%
1,497 $157,000
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $591 - $750
6 Added 0.41%
1,480 $160,000
Q2 2023

Aug 14, 2023

SELL
$102.58 - $129.66 $564,600 - $713,648
-5,504 Reduced 78.88%
1,474 $159,000
Q1 2023

May 15, 2023

BUY
$122.57 - $153.67 $89,598 - $112,332
731 Added 11.7%
6,978 $869,000
Q4 2022

Feb 21, 2023

BUY
$118.43 - $186.05 $48,793 - $76,652
412 Added 7.06%
6,247 $938,000
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $112,587 - $161,503
882 Added 17.81%
5,835 $787,000
Q2 2022

Aug 04, 2022

BUY
$123.25 - $186.24 $57,311 - $86,601
465 Added 10.36%
4,953 $738,000
Q1 2022

May 09, 2022

BUY
$126.25 - $231.85 $565,978 - $1.04 Million
4,483 Added 89660.0%
4,488 $765,000
Q4 2021

Feb 03, 2022

BUY
$216.64 - $362.52 $1,083 - $1,812
5 New
5 $1,000
Q2 2021

Aug 13, 2021

SELL
$113.32 - $241.49 $7,025 - $14,972
-62 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$85.73 - $119.5 $5,315 - $7,409
62 New
62 $7,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Northwestern Mutual Wealth Management CO Portfolio

Follow Northwestern Mutual Wealth Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northwestern Mutual Wealth Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Northwestern Mutual Wealth Management CO with notifications on news.